Nobuo Aoki

Q: What Schools Are Affiliated With Nobuo Aoki

Nobuo Aoki is affiliated with the following schools: Kyorin University, Thomas Jefferson University

Nobuo Aoki's AcademicInfluence.com Rankings

Nobuo Aoki

Philosophy

#8691

World Rank

#12116

Historical Rank

Logic

#5721

World Rank

#7143

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Nobuo Aoki's Degrees

PhD Medicine University of Tokyo
Doctorate Medicine University of Tokyo

Why Is Nobuo Aoki Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nobuo Aoki's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial (2007) (532)
Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. (1990) (516)
Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. (1976) (408)
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. (1980) (361)
Mediation of cardioprotection by transforming growth factor-beta. (1990) (307)
Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. (1982) (284)
Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. (1978) (241)
A novel vascular relaxing agent, N-(6--aminohexyl)-5-chloro-1-naphthalensulfonamide which affects vascular smooth muscle actomyosin. (1978) (172)
Congenital Deficiency of α2-Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency (1979) (170)
Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. (1987) (147)
A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. (1997) (139)
The behavior of alpha2-plasmin inhibitor in fibrinolytic states. (1977) (131)
Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. (1989) (129)
Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. (1986) (124)
Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. (1982) (123)
Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. (1997) (118)
Acute effects of cigarette smoking on platelet-dependent thrombin generation. (2001) (117)
THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION: SUBANALYSIS FROM THE PHASE 3 TRIAL (2011) (109)
Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. (1997) (104)
Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. (1996) (98)
Factor XIII‐mediated cross‐linking of NH2‐terminal peptide of α2‐plasmin inhibitor to fibrin (1983) (98)
Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. (1982) (93)
Beneficial effects of two forms of NO administration in feline splanchnic artery occlusion shock. (1990) (93)
Natural inhibitors of fibrinolysis. (1979) (91)
Conformation-specific monoclonal antibodies to the calcium-induced structure of protein C. (1986) (89)
Effect of Protein C and Activated Protein C on Coagulation and Fibrinolysis in Normal Human Subjects (1990) (89)
Platelet-dependent thrombin generation in patients with hyperlipidemia. (1997) (86)
Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor (1981) (84)
A Comparative Double-Blind Randomized Trial of Activated Protein C and Unfractionated Heparin in the Treatment of Disseminated Intravascular Coagulation (2002) (84)
Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. (1978) (74)
DISTRIBUTION OF COLD‐INSOLUBLE GLOBULIN IN PLASMA AND TISSUES * (1978) (73)
Expression and characterization of pro alpha 2-plasmin inhibitor. (1989) (63)
Congenital α2‐plasmin inhibitor deficiencies: a review (2001) (62)
Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro (1991) (61)
Inhibition of plasminogen binding to fibrin by α2-plasmin inhibitor☆ (1977) (61)
Assay of alpha2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate. (1978) (59)
Purpura fulminans in a Chinese boy with congenital protein C deficiency. (1986) (59)
Fibrinolytic States in a Patient with Congenital Deficiency of Alpha 2-Plasmin Inhibitor (1980) (55)
Molecular basis for Glanzmann's thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex. (1992) (54)
Treatment of patients with disseminated intravascular coagulation by protein C (1990) (52)
Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin. (1978) (52)
Acceleration of fibrinolysis by the N-terminal peptide of alpha 2-plasmin inhibitor. (1985) (51)
Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. (1990) (49)
Hemostasis associated with abnormalities of fibrinolysis. (1989) (49)
Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. (1994) (48)
Excessive fibrinolysis in suspected amyloidosis: Demonstration of plasmin‐α2‐plasmin inhibitor complex and von Willebrand factor fragment in plasma (1986) (46)
Organization of the human alpha 2-plasmin inhibitor gene. (1988) (45)
Molecular abnormality of plasminogen. (1980) (45)
Congenital alpha(2)-plasmin inhibitor deficiencies: a review. (2001) (45)
Effects of α2-Plasmin Inhibitor on Fibrin Clot Lysis. Its Comparison with α2-Macroglobulin (1978) (44)
Inhibitory spectrum of alpha 2-plasmin inhibitor. (1979) (44)
Molecular basis for Glanzmann's thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex (1992) (42)
Review of a case of tsutsugamushi disease showing myocarditis and confirmation of Rickettsia by endomyocardial biopsy. (1991) (41)
Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site. (1988) (41)
Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation (1978) (41)
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. (1984) (40)
Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. (1979) (39)
Autoantibody against platelet glycoprotein IIb/IIIa in a patient with non-Hodgkin's lymphoma. (1989) (38)
Reversible cross-linking of α2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor (1982) (36)
Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis. (1986) (34)
Histidine-rich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin. (1984) (30)
Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. (1983) (30)
Mental stress and physical exercise increase platelet-dependent thrombin generation (2000) (29)
Anti-Shock Effects of Human Superoxide Dismutase in Splanchnic Artery Occlusion (SAO) Shock (1988) (29)
Influence of α2-plasmin inhibitor on adsorption of plasminogen to fibrin (1980) (29)
Alpha 2-Plasmin inhibitor is among acute phase reactants. (1980) (29)
Preparation of thrombomodulin from human placenta. (1985) (29)
Direct cardiovascular actions of two metabolites of linoleic acid. (1990) (28)
Preparation of plasminogen activator from vascular trees of human cadavers. Its comparison with urokinase. (1974) (27)
Thrombasthenia with an abnormal platelet membrane glycoprotein IIb of different molecular weight. (1988) (26)
Frequencies of prothrombin 20210 G-->A mutation may be different among races--studies on Japanese populations with various forms of thrombotic disorders and healthy subjects. (1998) (26)
Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression. (1998) (24)
Monoclonal antibodies to human thrombomodulin whose binding is calcium dependent. (1989) (24)
Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. (1981) (24)
Plasminogens Tochigi II and Nagoya: two additional molecular defects with Ala-600----Thr replacement found in plasmin light chain variants. (1984) (24)
Restriction fragment length polymorphism caused by a deletion involving Alu sequences within the human alpha 2-plasmin inhibitor gene. (1989) (24)
On the interaction of alpha2-plasmin inhibitor and proteases. Evidence for the formation of a covalent crosslinkage and non-covalent weak bondings between the inhibitor and proteases. (1977) (23)
Relationship between post‐translational glycosylation and anticoagulant function of secretable recombinant mutants of human thrombomodulin (1991) (23)
Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial (2015) (23)
Discovery of α2‐plasmin inhibitor and its congenital deficiency (2004) (23)
Urinary thrombomodulin, its isolation and characterization. (1993) (22)
Leukocyte-dependent and leukocyte-independent mechanisms of impairment of endothelium-mediated vasodilation. (1990) (21)
Treatment of DIC with antithrombin III concentrates. (1983) (21)
Shear‐induced platelet aggregation increases in patients with proximal and severe coronary artery stenosis (2002) (20)
The alpha2-plasmin inhibitor levels in liver diseases. (1978) (20)
Fibrinolysis: Its initiation and regulation (1986) (19)
Potentiation by collagen or epinephrine of platelet responsiveness to aggregation. The possible role of substance(s) released from platelet membranes. (1977) (19)
Fibrin-associated plasminogen activation in alpha 2-plasmin inhibitor deficiency (1983) (19)
Structure of the Carboxyl-Terminal Half of Human α2-Plasmin Inhibitor Deduced from That of cDNA (1986) (18)
Inhibition of proteases in coagulation, kinin-forming and complement systems by alpha2-plasmin inhibitor. (1977) (18)
Differences of frequency distributions of plasminogen phenotypes between Japanese and American populations: New methods for the detection of plasminogen variants (1984) (17)
The past, present and future of plasmin inhibitor. (2005) (17)
Anti-shock effects of human superoxide dismutase in splanchnic artery occlusion (SAO) shock. (1988) (16)
Localization of urinary procoagulant in the human kidney. (1979) (16)
Reversible cross-linking of alpha 2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor. (1982) (15)
The link between free radicals and myocardial injury. (1988) (15)
Inhibition of platelet function by a calmodulin interacting agent, W-7. (1981) (15)
Genetic polymorphism of human plasminogen in a Japanese population. (1982) (15)
Protection of the rat myocardium from ischemic injury by dietary lamprey oil. (1988) (14)
Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X. (1984) (14)
Cross-linking of cxz-Plasmin Inhibitor to Fibrin Catalyzed by Activated Fibrin-stabilizing Factor * (2001) (13)
Clot Retraction Increases Clot Resistance to Fibrinolysis by Condensing α2-Plasmin Inhibitor Crosslinked to Fibrin (1993) (13)
Heterozygote for plasmin inhibitor deficiency developing hemorrhagic tendency with advancing age. (1996) (12)
FUNCTION OF AC-GLOBULIN AND LIPID IN BLOOD CLOTTING. (1963) (12)
Purification and characterization of procoagulant in human urine. (1978) (11)
Clinical Pharmacology of a New Antithrombotic Agent, Ticlo (1978) (11)
Influence of alpha 2-plasmin inhibitor on adsorption of plasminogen to fibrin. (1980) (10)
Calcium-dependent binding of α2-plasmin inhibitor to fibrin (1979) (10)
Isolation and Characterization of a 2-Plasmin Inhibitor from Human Plasma (2002) (10)
Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation. (1978) (10)
Association of human alpha1-antitrypsin with anhydrotrypsin. (1975) (10)
Human alpha 2-plasmin inhibitor. (1993) (9)
Mechanism of Rethrombosis After Thrombolytic Therapy: Angioscopic Findings and Investigation of the Coagulation System in Dogs (1998) (9)
Distinction of Serum Inhibitor of Activator-Induced Clot Lysis from α1-Antitrypsin (1974) (9)
Molecular genetics of alpha 2 plasmin inhibitor. (1990) (8)
[A case of acute promyelocytic leukemia with skin nodules and mammary tumors during hematologic remission (author's transl)]. (1978) (8)
Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion (1990) (8)
Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system (1995) (8)
Chronic lymphocytic leukemia of T-cell origin: demonstration in two cases by the use of anti-thymocyte membrane antiserum. (1974) (8)
Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock. (1988) (8)
A Single Thymine Nucleotide Deletion Responsible for Congenital Deficiency of Plasmin Inhibitor (2002) (8)
Fibrin-associated plasminogen activation in alpha 2-plasmin inhibitor deficiency. (1983) (7)
Assignment of the human alpha 2-plasmin inhibitor gene (PLI) to chromosome region 18p11.1----q11.2 by in situ hybridization. (1988) (7)
A Novel Polymorphism, 70Leu/Phe, Disrupts a Consensus Leu Residue within the Leucine-rich Repeat Sequence of Platelet Glycoprotein Ibα (2002) (7)
Discovery of alpha2-plasmin inhibitor and its congenital deficiency. (2005) (6)
Survival of transfused α2-plasmin inhibitor in a patient with its congenital deficiency (1981) (6)
PROVEST AND BLOOD COAGULATION TESTS. (1963) (6)
Statistics on underlying and causative diseases of DIC in Japan: a cooperative study. (1983) (5)
Antithrombin III concentrate in the treatment of fulminant hepatic failure (1988) (5)
The initiation of fibrinolysis in α2-plasmin inhibitor deficient plasma. Role of fibrin (1986) (5)
Purification of Human α2 -Plasmin Inhibitor Using Monoclonal Antibody Column Chromatography (1989) (5)
Fundamental Function of Ac-globulin and Lipid in Blood Clotting (1963) (4)
Calcium-dependent binding of alpha 2-plasmin inhibitor to fibrin. (1979) (4)
Structure of the carboxyl-terminal half of human alpha 2-plasmin inhibitor deduced from that of cDNA. (1986) (4)
[Assessment of global and regional LV function obtained by quantitative gated SPECT using 99mTc-tetrofosmin: comparison with left ventricular cineangiography and echocardiography]. (1998) (4)
Clinical Significance of Hypoxemia without Congestive Heart Failure in Patients Presenting with Acute Myocardial Infarction (1997) (4)
Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock. (1988) (3)
Inhibition of plasminogen binding to fibrin by alpha2-plasmin inhibitor. (1977) (3)
[Evaluation of the assay for alpha 2PI and alpha 2PI-plasmin complex using the one-step sandwich method (EIA)]. (1987) (3)
Effects of repeated brief episodes of ischemia and reperfusion in isolated perfused rat hearts (2006) (3)
Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock. (1989) (3)
Fibrin-Associated Plasminogen Activation in a 2 Pli min Inhibitor Deficiency (2005) (3)
Platelet-Dependent Thrombin Generation in Patients with Unstable Angina Pectoris (2001) (2)
FIBRINOGENS KYOTO AND TOCHIGI, EACH WITH AN APPARENT ABNORMAL MOL. WT. γ CHAIN, ARE CHARACTERIZED BY REPLACEMENT OF γ ASN-308 BY LYS AND γ ARG-275 BY CYS, RESPECTIVELY (1987) (2)
Purification of human alpha 2-plasmin inhibitor by a one-step immunoaffinity chromatography procedure. (1992) (2)
Release of Arachidonic Acid From Human Platelets (2005) (2)
Identification of free radical species in the myocardium. (1988) (2)
[Pathogenesis of von Willebrand's disease]. (1978) (1)
STRUCTURE OF HUMAN α2-PLASMIN INHIBITOR DEDUCED FROM THAT OF cDNA (1987) (1)
α2-Plasmin Inhibitor: A Novel Inhibitor of Blood Coagulation and Kinin Generation (1977) (1)
A case of dermatomyositis associated with recurrent mediastinal emphysema (1986) (1)
Plasma level of cold-insoluble globulin in liver diseases, especially in liver cirrhosis and its clinical implications (1981) (1)
Japanese not hypersensitive to warfarin. (1971) (1)
The initiation of fibrinolysis in alpha 2-plasmin inhibitor deficient plasma. Role of fibrin. (1986) (1)
[Molecular abnormalities of coagulation-fibrinolysis factors]. (1980) (1)
Hypertension and dietary habit (1988) (1)
Direct positive inotropic and vasoconstrictor effects of endothelin (2005) (1)
α2-Plasmin inhibitor: Inhibitory regulator of fibrinolytic system (1986) (1)
The Behavior of a2-Plasmin Inhibitor in Fibrinolytic States (2013) (1)
[The determination of antiactivator; especially inhibitors against the activator-induced fibrin clot lysis (author's transl)]. (1976) (0)
[An autopsy case of adult T-cell leukemia with extensive involvement of the lung (author's transl)]. (1980) (0)
[Effects of alpha2-macroglobulin and FDP on the antithrombin III assay system (author's transl)]. (1977) (0)
Klippel-Trénaunay-Weber Syndrome Complicated by DIC Associated with Bone Fracture (1991) (0)
Purification of human alpha 2-plasmin inhibitor using monoclonal antibody column chromatography. (1989) (0)
-255-A RAPID AND SINPLE TECHNIQUE FOR THE IDENTIFICATION OF NECROTIC AREA WITH NADH FLUOROPHOTOGRAPHY AND NAD^+ & NADH VALUES IN THE MYOCARDIUM (1986) (0)
[The use of antithrombin III concentrates in disseminated intravascular coagulation]. (1982) (0)
[alpha2-plasmin inhibitor (author's transl)]. (1978) (0)
Distribution And Localization Of Urinary Procoagulant In The Human Kidney And Its Immunologically Cross-Reactive Substances In Various Exocrine Glands (1981) (0)
[Evaluation of quantitative analysis of serum protein by immunological methods]. (1971) (0)
BRIEF COMMUNICATION PURIFICATION OF HUMAN an-PLASMIN INHIBITOR BY A ONE-STEP IMMUNOAFFINITY CHROMATOGRAPHY PROCEDURE (1992) (0)
[Changes of parameters of coagulation and fibrinolysis in disseminated intravascular coagulation]. (1973) (0)
[Thrombotic tendency due to congenital disorders of coagulation or fibrinolysis (author's transl)]. (1980) (0)
A case of platelet GPIIb/IIIa abnormality which shows lag time in ADP-induced aggregation (1987) (0)
Dispositif d’alimentation en carburant (2005) (0)
Status of the Research in the Field of Thrombosis and Hemostasis in Japan—Retrospective and Prospective Overviews (1997) (0)
fibrins: its significance in hemostatic defect in factor XIII deficiency Differential binding of plasminogen to crosslinked and noncrosslinked (2011) (0)
[Hypertension and stroke: screening methods]. (1980) (0)
[Sustained high fever and hepatosplenomegaly: reactive reticulosis with appearance of Hodgkin-type cells]. (1975) (0)
Immunological Difference between Blood and Placental Urokinase Inhibitor of Pregnant Women (1977) (0)
Preparation of omega-(arylsulfonamido)-alkylamides (1975) (0)
Acute effects of unsaturated fatty acids in splanchnic artery occlusion shock. (1989) (0)
Anticoagulant and Antiplatelet Therapy in the Aged (1986) (0)
Thrombomodulin: Its Expression and Releace into the Circulation (1993) (0)
Thrombosis and Blood Coagulation/Fibrinolysis (1980) (0)
Effects of Tissue Urokinase on Thrombin Plasminogen Activator and Human Platelet-dependent Generation in vitro (2014) (0)
Mechanism of Thromblysis (1982) (0)
Substance that binds to thrombin and process for their preparation. (1987) (0)
[On the standardization in fibrinolysis assays (author's transl)]. (1976) (0)
Educational lecture on hereditary abnormalities of blood coagulation and thrombosis. (1987) (0)
[Early chest x-ray findings of ARDS--retrospective study on pulmonary complication of DIC (author's transl)]. (1980) (0)
Throminbindende substance and process for their preparation. (1987) (0)
Pompe d'alimentation en carburant (2005) (0)
Hybridoma capable of producing monoclonal antibody for anti-thrombin binding substance (1992) (0)
A case of acute promyelocytic leukemia (APL) followed by microgranular type APL. (1983) (0)
[Endothelial damage and repair in myocardial ischemia and reperfusion]. (1993) (0)
The plasma beta-thromboglobulin in ischemic heart disease (1980) (0)
Proceedings: Inhibition of platelet cyclic AMP phosphodiesterase and platelet aggregation. (1974) (0)
[Clinical problems of the natural coagulation and fibrinolysis inhibitors--introduction (author's transl)]. (1978) (0)
[Progress in diagnosis of disseminated intravascular coagulation (DIC)--diagnostic criteria of DIC]. (1993) (0)
[Releasing function of the platelets (with special reference to 14C-serotonin release]. (1979) (0)
Genetic risk factors for coronary artery disease (1998) (0)
[Serum protein fraction values and frequency of M-protein isolation in geriatric examinations]. (1971) (0)
[Hereditary abnormalities of blood coagulation and thrombosis]. (1987) (0)
Survival of transfused alpha 2-plasmin inhibitor in a patient with its congenital deficiency. (1981) (0)
Monoclonal antibodies against Antithrombinbindende substance and its uses. (1988) (0)
Recent progress in hematology. DIC. (1987) (0)
Preparation of plasminogen - free fibrinogen; starting from fibrinogen prepared by improved freezing thawing method. (1969) (0)
Potentiation by collagen or epinephrine of platelet responsiveness to aggregation. The possible role of arachidonic acid released from platelet membranes (1977) (0)
CLINICAL SIGNIFICANCE OF HYPOXIA WITHOUT CONGESTIVE HEART FAILURE IN ACUTE MYOCARDIAL INFARCTION (1995) (0)
Reminiscences of my contributions to Thrombosis and Haemostasis: Urine tissue factor and plasma plasmin inhibitor (2007) (0)
[Algorithm for calculating blood base excess from pH bicarbonate diagram (author's transl)]. (1980) (0)
[Review of recent studies of hemostasis and the mechanism of thrombosis]. (1974) (0)
-35- MECHANISM OF PROTECTION OF REPERFUSION INJURY BY FREE RADICAL SCAVENGER : ROLE OF ENDOTHELIAL CELL PRESERVATION : Coronary Circulation : FREE COMMUNICATIONS(I) : PROCEEDINGS OF THE 51th ANNUAL SCIENTIFIC MEETING OF THE JAPANESE CIRCULATION SOCIETY (1987) (0)
[Studies on the regulatory mechanisms of platelet aggregation (author's transl)]. (1979) (0)
[Review on internal medicine (1986). Recent progress in hematology. 7. DIC]. (1987) (0)
Peptide of a2-Plasmin Inhibitor (2005) (0)
α 2 -Makroglobulin und Protease Nexin 1: Struktur und Funktion (1999) (0)
[Puncture biopsy of the kidney and prostatic neoplasms]. (1980) (0)
Thrombin-binding substance and process for preparing thethrombin-binding substance and process for preparing the same same (1987) (0)
[Reactions of alpha 2 plasmin inhibitor to plasmin and fibrin; its significance in fibrinolysis inhibition and hemostasis]. (1982) (0)
different molecular weight Thrombasthenia with an abnormal platelet membrane glycoprotein IIb of (2005) (0)
Augmentation of thrombin generation during exercise or mental stress (1996) (0)
[Clinical and laboratory studies on cefoxitin in the field of digestive system (author's transl)]. (1980) (0)
Two cases of connective tissue diseases complicated with thrombotic thrombocytopenic purpura (1990) (0)
[Cortisol measurement using solid-phase radioimmunoassay (author's transl)]. (1981) (0)
[A family of hereditary refractory sideroblastic anemia with markedly reduced delta-aminolevulinic acid synthetase activity in bone marrow erythroblasts]. (1976) (0)
Effects of Tissue Plasminogen Activator and Urokinase on Human Platelet-dependent Thrombin Generation in vitro (2000) (0)
[Antithrombin 3. Its physicochemical properties and pathophysiological significance (author's transl)]. (1973) (0)
Efficacy and Safety of Recombinant Human Soluble Thrombomodulin (ART-123) in Disseminated Intravascular Coagulation (DIC): Results of Phase III Randomized, Double-Blind, Clinical Trial. (2006) (0)
-46-IDENTIFICATION AND QUANTIFICATION OF FREE RADICALS IN THE MYOCARDIUM WITH ESR SIGNALS (1986) (0)
Studies for Mechanisms of Impaired Secretion of α2-Plasmin Inhibitor (1996) (0)
[The biochemistry of fibrinolysis]. (1966) (0)
[Protein C--possible usefulness as a therapeutic weapon]. (1990) (0)
[Dic, thrombophlebitis--paraneoplastic syndromes---statistics and etiological mechanism]. (1980) (0)
[Mechanism of hemostasis and thrombosis formation]. (1991) (0)
[Electrophoresis of immunoglobulins, with special reference to M-protein]. (1972) (0)
Reperfusion in Cats (2005) (0)
[New trend of research on thrombosis and hemostasis; molecular biology]. (1989) (0)
[Changes in blood chemical components in the aged]. (1971) (0)
[Thrombolytic mechanism and its therapeutic application]. (1986) (0)
[Emergency tests. The clinicopathological viewpoint: the standpoint of the general hospital]. (1974) (0)
[Pathophysiology and treatment of thrombosis. (3) Protein C deficiency and thrombosis]. (1987) (0)
[Standard value of prolactin and significance of metoclopramide test, with special reference to normal subjects and patients with thyroid diseases]. (1977) (0)
[Radioimmunoassay of serum free thyroxine with microencapsulation system--its clinical use]. (1982) (0)
[The change of antithrombin III activity of pregnant women and women on oral contraceptives (author's transl)]. (1977) (0)
Distinction of Plasma Inhibitor of Activator-Induced Clot Lysis from Antiplasmins (1975) (0)
[Contribution of Japanese researchers to progress in the field of hematology in the last 100 years: Congenital deficiency of alpha2-plasmin inhibitor]. (2002) (0)
[Analysis in the coronary artery resistance during reperfusion after myocardial ischemia]. (1988) (0)
Detection of plasminogen variants by electrofocusing and frequency distribution of plasminogen phenotypes (1984) (0)
.omega.-(ARYLSULFAMIDE)-ALKYLAMINE (1975) (0)
Monoclonal antibodies binding substance antithrombin and their uses. (1988) (0)
Benign intracranial hypertension. (1985) (0)
[A case of ankylosing spondylitis associated with hyperthyroidism and mesangial proliferative glomerulonephritis]. (1987) (0)
[Study on the cell morphology and serum viscosity in myeloma, with special reference to the significance of enlarged rough endoplasmic reticulum]. (1968) (0)
Anticorps monoclonaux contre une substance se liant a la thrombine, hybridomes produisant ces anticorps, methode de purification et detection de la substance se liant a la thrombine a l'aide de ces anticorps monoclonaux (1988) (0)
News omega- (arylsulfonamido) alkylamine, their process for the preparation and application in therapeutic (1975) (0)
1006-44 A Prognostic Factor in Coronary Artery Disease (CAD): Platelet-Dependent Thrombin Generation in Patients with CAD (1995) (0)
3) Protein C Deficiency and Thrombosis (1987) (0)
[Analysis of alpha 2-plasmin inhibitor]. (1985) (0)
[Blood concentrations of thrombomodulin in patients with various diseases]. (1994) (0)
A case of Crohn's disease associated with Sjögren's syndrome, who in addition met the diagnostic criteria for systemic lupus erythematosus (1992) (0)
[Role of adenylate cyclase and the mechanism controlling platelet aggregation]. (1979) (0)
Inhibition Of Platelet Aggregation And Release Reaction By A Calmodulin Interacting Agent, N-(6-Aminohexyl)-5-Chloro-1-Naphthalene Sulfonamide (1981) (0)
Clinical Valuableness of the Measurement of Thrombin/Antithrombin III Complex (1990) (0)
Isolation and characterization of α2-plasmin inhibitor brom human plasma (1978) (0)
[Pathophysiological analysis of diabetes mellitus and complications from the urine of diabetic patients]. (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nobuo Aoki?

Nobuo Aoki is affiliated with the following schools: